XML 48 R27.htm IDEA: XBRL DOCUMENT v2.4.1.9

COLLABORATION AND LICENSE AGREEMENT (Details) (USD $)	0 Months Ended
	Dec. 15, 2014 item	Mar. 31, 2015	Dec. 31, 2014
LICENSE AGREEMENTS
Amount expected to be recognized as revenue		$ 35,000,000us-gaap_DeferredRevenueCurrent	$ 35,000,000us-gaap_DeferredRevenueCurrent
Accrued collaboration charges		626,000gern_CollaborativeArrangementAccruedCollaborationChargesCurrent
Expected Revenue
LICENSE AGREEMENTS
Amount expected to be recognized as revenue		35,000,000us-gaap_DeferredRevenueCurrent / us-gaap_StatementScenarioAxis = gern_CollaborativeArrangementExpectedRevenueMember
License agreements | Janssen Biotech | Initial Period
LICENSE AGREEMENTS
Upfront payment received	35,000,000gern_UpfrontPaymentReceivedFromJanssenUnderCollaborationAgreement / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_InitialPeriodMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Number of agreed upon studies	2gern_CollaborativeArrangementNumberOfStudies / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_InitialPeriodMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Percentage of costs to be paid by Geron	50.00%gern_CollaborativeArrangementGeronCostSharingPercentage / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_InitialPeriodMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Percentage of costs to be paid by Janssen	50.00%gern_CollaborativeArrangementJanssenCostSharingPercentage / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_InitialPeriodMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Notification period	24 months
Maximum period Geron is obligated to procure supply for manufacturing imetelstat under collaboration agreement	9 months
License agreements | Janssen Biotech | U.S. Opt-In Rights exercised
LICENSE AGREEMENTS
Percentage of costs to be paid by Geron	20.00%gern_CollaborativeArrangementGeronCostSharingPercentage / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Percentage of costs to be paid by Janssen	80.00%gern_CollaborativeArrangementJanssenCostSharingPercentage / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Continuation Election milestone payment	65,000,000gern_CollaborativeArrangementContinuationElectionMilestonePayment / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Aggregate maximum total payments for development and regulatory milestones under collaboration agreement	470,000,000gern_CollaborativeArrangementDevelopmentAndRegulatoryMilestonesAggregateMaximum / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Aggregate maximum total of payments for sales milestones under collaboration agreement	350,000,000gern_CollaborativeArrangementSalesMilestonesAggregateMaximum / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Tiered royalties percentage, low end of the range	mid-teens
Tiered royalties percentage, high end of the range	low twenties
U.S. selling effort percentage	20.00%gern_CollaborativeArrangementSellingEffortPercentage / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
License agreements | Janssen Biotech | U.S. Opt-In Rights not exercised
LICENSE AGREEMENTS
Continuation Election milestone payment	65,000,000gern_CollaborativeArrangementContinuationElectionMilestonePayment / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsNotExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Full U.S. Rights fee	70,000,000gern_CollaborativeArrangementFullUSRightsFee / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsNotExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Aggregate maximum total payments for development and regulatory milestones under collaboration agreement	415,000,000gern_CollaborativeArrangementDevelopmentAndRegulatoryMilestonesAggregateMaximum / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsNotExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Aggregate maximum total of payments for sales milestones under collaboration agreement	$ 350,000,000gern_CollaborativeArrangementSalesMilestonesAggregateMaximum / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsNotExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Tiered royalties percentage, low end of the range	double-digit
Tiered royalties percentage, high end of the range	mid-teens
License agreements | Janssen Biotech | Collaborative Arrangement IP Exclusively Licensed
LICENSE AGREEMENTS
Percentage of costs to be paid by Geron	50.00%gern_CollaborativeArrangementGeronCostSharingPercentage / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_CollaborativeArrangementIPExclusivelyLicensedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Percentage of costs to be paid by Janssen	50.00%gern_CollaborativeArrangementJanssenCostSharingPercentage / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_CollaborativeArrangementIPExclusivelyLicensedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable to collaboration partner for which invoices have not yet been received under the respective collaboration agreement (due within one year or within the normal operating cycle if longer).

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementAccruedCollaborationChargesCurrent
Namespace Prefix:	gern_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The amount of consideration that Geron will receive upon Janssen providing a positive Continuation Election notice.

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementContinuationElectionMilestonePayment
Namespace Prefix:	gern_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the aggregate maximum consideration that Geron could receive from attaining certain development and regulatory milestone events under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementDevelopmentAndRegulatoryMilestonesAggregateMaximum
Namespace Prefix:	gern_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the maximum period that Geron is obligated to Janssen to procure supply for manufacturing imetelstat under the collaboration agreement

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementDrugSupplyProcurementPeriodMaximum
Namespace Prefix:	gern_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the consideration that Geron will receive from Janssen upon Geron's decision to opt-out of further development cost sharing after Janssen's positive Continuation Election notice.

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementFullUSRightsFee
Namespace Prefix:	gern_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the percentage of costs that Geron must pay during certain phases of the agreement.

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementGeronCostSharingPercentage
Namespace Prefix:	gern_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the percentage of costs that Janssen must pay during certain phases of the agreement.

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementJanssenCostSharingPercentage
Namespace Prefix:	gern_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the latest notification period from Janssen to Geron in the event of early termination or suspension of the Initial Phase 2 MF Study.

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementNotificationPeriod
Namespace Prefix:	gern_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the number of agreed upon studies.

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementNumberOfStudies
Namespace Prefix:	gern_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the aggregate maximum consideration that Geron could receive from attaining certain sales milestone events under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementSalesMilestonesAggregateMaximum
Namespace Prefix:	gern_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the percentage of sales effort that Geron can provide in lieu of funding the same percentage of promotion costs upon regulatory approval and commercial launch of imetelstat in the U.S.

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementSellingEffortPercentage
Namespace Prefix:	gern_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the high end of the range of tiered royalty percentages to be applied to worldwide net sales of imetelstat.

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementTieredRoyaltiesPercentageHighEndOfRange
Namespace Prefix:	gern_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the low end of the range of tiered royalty percentages to be applied to worldwide net sales of imetelstat.

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementTieredRoyaltiesPercentageLowEndOfRange
Namespace Prefix:	gern_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Upfront payment received from Janssen upon effectiveness of Collaboration Agreement.

+ References

No definition available.

+ Details

Name:	gern_UpfrontPaymentReceivedFromJanssenUnderCollaborationAgreement
Namespace Prefix:	gern_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765



Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Details

Name:	us-gaap_CounterpartyNameAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementScenarioAxis=gern_CollaborativeArrangementExpectedRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: